AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Feb 13, 2023
32254_dirs_2023-02-13_ce74dfe8-254b-4bc9-972f-976e4c21e317.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-02-09
Reporting Person: DICICCO WENDY F (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-09 | Common Stock | M | 3000.00 | $0.00 | Acquired | 7400.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-09 | Restricted Stock Units | $0.00 | M | 3000.00 | Disposed | Common Stock (3000.00) | Direct |
Footnotes
F1: Fully vested on the one-year anniversary of the grant date.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7